IL250251A0 - Compounds containing tricyclic nitrogen for the treatment of Neisseria gonorrhoeae infection - Google Patents

Compounds containing tricyclic nitrogen for the treatment of Neisseria gonorrhoeae infection

Info

Publication number
IL250251A0
IL250251A0 IL250251A IL25025117A IL250251A0 IL 250251 A0 IL250251 A0 IL 250251A0 IL 250251 A IL250251 A IL 250251A IL 25025117 A IL25025117 A IL 25025117A IL 250251 A0 IL250251 A0 IL 250251A0
Authority
IL
Israel
Prior art keywords
containing compounds
nitrogen containing
neisseria gonorrhoea
tricyclic nitrogen
treating neisseria
Prior art date
Application number
IL250251A
Other languages
English (en)
Hebrew (he)
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of IL250251A0 publication Critical patent/IL250251A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL250251A 2014-08-22 2017-01-23 Compounds containing tricyclic nitrogen for the treatment of Neisseria gonorrhoeae infection IL250251A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462040488P 2014-08-22 2014-08-22
PCT/IB2015/056325 WO2016027249A1 (en) 2014-08-22 2015-08-20 Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

Publications (1)

Publication Number Publication Date
IL250251A0 true IL250251A0 (en) 2017-03-30

Family

ID=54072911

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250251A IL250251A0 (en) 2014-08-22 2017-01-23 Compounds containing tricyclic nitrogen for the treatment of Neisseria gonorrhoeae infection

Country Status (22)

Country Link
US (2) US10702521B2 (cg-RX-API-DMAC7.html)
EP (2) EP3639824A1 (cg-RX-API-DMAC7.html)
JP (2) JP6546654B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170043603A (cg-RX-API-DMAC7.html)
CN (2) CN106659717B (cg-RX-API-DMAC7.html)
AR (1) AR101674A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015304847B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017003705B1 (cg-RX-API-DMAC7.html)
CA (1) CA2958800C (cg-RX-API-DMAC7.html)
CL (1) CL2017000391A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017001658A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170069A (cg-RX-API-DMAC7.html)
DO (1) DOP2017000049A (cg-RX-API-DMAC7.html)
EA (1) EA031589B1 (cg-RX-API-DMAC7.html)
ES (1) ES2759303T3 (cg-RX-API-DMAC7.html)
IL (1) IL250251A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017002321A (cg-RX-API-DMAC7.html)
PE (1) PE20170501A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500315A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201700566SA (cg-RX-API-DMAC7.html)
TW (1) TW201618779A (cg-RX-API-DMAC7.html)
WO (1) WO2016027249A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017003705B1 (pt) * 2014-08-22 2022-07-12 Glaxosmithkline Intellectual Property Development Limited Compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
JP2019517546A (ja) * 2016-06-08 2019-06-24 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニAziende Chimiche Riunite Angelini Francesco A.C.R.A.F.Societa Per Azioni 新しい抗菌性化合物
RU2019121534A (ru) 2016-12-16 2021-01-18 Басф Се Пестицидные соединения
US20220184071A1 (en) * 2019-04-03 2022-06-16 Glaxosmithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
WO2020201833A1 (en) * 2019-04-03 2020-10-08 Glaxomithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
GB201909191D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CA3143619A1 (en) * 2019-07-05 2021-01-14 Glaxosmithkline Intellectual Property Development Limited Combination for the treatment of infections caused by mycoplasma genitalium
IL293340A (en) 2019-12-02 2022-07-01 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors
BR112022018315A2 (pt) * 2020-04-02 2022-10-25 Glaxosmithkline Ip Dev Ltd Regime para tratar a infecção por neisseria gonorrhoeae com gepotidacina
WO2021219671A1 (en) * 2020-04-28 2021-11-04 Noorik Biopharmaceuticals Ag Treatment of pulmonary complications of coronavirus infections
JP7682923B2 (ja) * 2020-04-29 2025-05-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ゲポチダシンの結晶形態
BR112023015676A2 (pt) * 2021-02-05 2023-10-17 Glaxosmithkline Ip Dev Ltd Formulações orais em dose sólida
EP4316463A1 (en) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation
JP2025532252A (ja) 2022-09-26 2025-09-29 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 処置方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090767A1 (en) 1992-03-06 1993-09-07 Gerald Guillaumet 1,4-dioxino[2,3-b]pyridine derivatives
EP0624376B1 (en) * 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
GB0207450D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
DE60025048D1 (de) 2000-07-21 2006-01-26 Ljudmila Petrovna Maljuk Teller für stehempfänge
CN1452619A (zh) 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
CZ20031194A3 (cs) 2000-09-29 2003-08-13 Glaxo Group Limited Deriváty močoviny
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
WO2002050036A1 (en) 2000-12-21 2002-06-27 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
ATE463494T1 (de) 2002-10-10 2010-04-15 Morphochem Ag Komb Chemie Neue verbindungen mit antibakterieller aktivität
AU2003303956A1 (en) 2002-11-05 2004-11-23 Smithkline Beecham Corporation Antibacterial agents
US7618959B2 (en) 2002-11-05 2009-11-17 Smithklinebeecham Corp Antibacterial agents
TW200427688A (en) 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1796466A4 (en) 2004-06-15 2009-09-02 Glaxo Group Ltd ANTIBACTERIAL AGENTS
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
JP2008505920A (ja) 2004-07-08 2008-02-28 グラクソ グループ リミテッド 抗菌剤
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
WO2006017326A1 (en) 2004-07-13 2006-02-16 Glaxo Group Limited Antibacterial agents
WO2006012396A1 (en) 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
WO2006017468A2 (en) 2004-08-02 2006-02-16 Glaxo Group Limited Antibacterial agents
US20070161627A1 (en) 2004-08-09 2007-07-12 Miller William H Antibacterial agents
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
CA2580621A1 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
JP2008515796A (ja) 2004-10-05 2008-05-15 アクテリオン ファーマシューティカルズ リミテッド 新規なピペリジン系抗生物質
WO2006046552A1 (ja) 2004-10-27 2006-05-04 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
US7648980B2 (en) 2005-01-25 2010-01-19 Glaxo Group Limited Antibacterial agents
US7709472B2 (en) 2005-01-25 2010-05-04 Glaxo Group Limited Antibacterial agents
US7605169B2 (en) 2005-01-25 2009-10-20 Glaxo Group Limited Antibacterial agents
WO2006081289A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
EP1846418A4 (en) 2005-01-25 2009-12-23 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
NZ562034A (en) 2005-03-31 2009-10-30 Janssen Pharmaceutica Nv Bicyclic pyrazole compounds as antibacterial agents
AR053602A1 (es) 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
JP2008542249A (ja) 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ 抗細菌活性を持つアミノピペリジンキノリン及びそのアザ等立体類似体
CN101180298B (zh) 2005-05-25 2011-04-27 埃科特莱茵药品有限公司 抗生素衍生物
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP1900732A4 (en) 2005-06-24 2009-11-18 Toyama Chemical Co Ltd NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
SI1954697T1 (sl) 2005-10-21 2010-05-31 Glaxo Group Ltd Peri kondenzirane triciklične spojine uporabne kot antibakterijska sredstva
WO2007067511A2 (en) 2005-12-06 2007-06-14 Merck & Co., Inc. Morpholine carboxamide prokineticin receptor antagonists
US20070185153A1 (en) 2005-12-22 2007-08-09 Nathalie Cailleau Compounds
JP2009532504A (ja) 2006-04-06 2009-09-10 グラクソ グループ リミテッド 抗菌薬
ATE481406T1 (de) 2006-04-06 2010-10-15 Glaxo Group Ltd Pyrrolochinoxalinonderivate als antibakterielle mittel
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
US20100256124A1 (en) 2006-06-09 2010-10-07 David Thomas Davies Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
KR101567096B1 (ko) * 2007-04-20 2015-11-06 글락소 그룹 리미티드 항균제로서의 트리시클릭 질소 함유 화합물
JP5474941B2 (ja) * 2008-05-23 2014-04-16 グラクソ グループ リミテッド 窒素含有三環式化合物およびその抗菌剤としての使用
JP2012505866A (ja) * 2008-10-17 2012-03-08 グラクソ グループ リミテッド 抗菌剤として使用される三環式窒素化合物
BR112017003705B1 (pt) * 2014-08-22 2022-07-12 Glaxosmithkline Intellectual Property Development Limited Compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea

Also Published As

Publication number Publication date
WO2016027249A1 (en) 2016-02-25
JP2017524029A (ja) 2017-08-24
EP3182973B1 (en) 2019-09-18
SG11201700566SA (en) 2017-03-30
CN106659717A (zh) 2017-05-10
JP2019189629A (ja) 2019-10-31
BR112017003705A2 (pt) 2017-12-05
EA201790442A1 (ru) 2017-08-31
US20200330462A1 (en) 2020-10-22
CA2958800A1 (en) 2016-02-25
AR101674A1 (es) 2017-01-04
US20170304301A1 (en) 2017-10-26
CR20170069A (es) 2017-04-28
MX2017002321A (es) 2017-08-02
CO2017001658A2 (es) 2017-07-19
CN110403939A (zh) 2019-11-05
US10702521B2 (en) 2020-07-07
PE20170501A1 (es) 2017-04-27
AU2015304847A1 (en) 2017-02-23
EP3182973A1 (en) 2017-06-28
EP3639824A1 (en) 2020-04-22
CL2017000391A1 (es) 2017-08-18
PH12017500315A1 (en) 2017-07-10
AU2015304847B2 (en) 2018-10-25
DOP2017000049A (es) 2017-03-15
JP6546654B2 (ja) 2019-07-17
TW201618779A (zh) 2016-06-01
BR112017003705B1 (pt) 2022-07-12
EA031589B1 (ru) 2019-01-31
US11229646B2 (en) 2022-01-25
ES2759303T3 (es) 2020-05-08
KR20170043603A (ko) 2017-04-21
CN106659717B (zh) 2019-09-06
CA2958800C (en) 2020-10-27

Similar Documents

Publication Publication Date Title
IL250251A0 (en) Compounds containing tricyclic nitrogen for the treatment of Neisseria gonorrhoeae infection
IL285077A (en) Compounds for the treatment of cancer
IL249229A0 (en) Compounds for the treatment of brain cancer
SG10201500647RA (en) Holding table
EP3354288C0 (en) STERILIZATION DEVICE
GB201502137D0 (en) Treatment
SI3368466T1 (sl) Naprava za obdelavo vsebnikov
GB201401430D0 (en) Treatment process
GB201411468D0 (en) Novel treatment for endometriosis
PL3186013T3 (pl) Urządzenie do obróbki przedmiotów
PL2949399T3 (pl) Urządzenie do obróbki artykułów drewnianych
GB201519450D0 (en) Novel treatment
SI3169457T1 (sl) Stroj za obdelavo vsebnikov
SG11201801456TA (en) Substrate treatment apparatus
GB201508841D0 (en) Treatment
GB201402909D0 (en) Treating infection
GB2534681B (en) Treatment apparatus
PL3129031T3 (pl) Kompozycja do terapii zaburzeń żołądkowych
GB201503008D0 (en) Treatment
GB201411027D0 (en) Treatment
ZA201704589B (en) Compounds for the treatment of cancer
IL249616A0 (en) Methods for treating inflammation
IL248782B (en) Thiazomycin compound treatment regimen
PL3194551T3 (pl) Stała kompozycja do traktowania tekstyliów
PT3142749T (pt) Composição para viscossuplementação compreendendo ulvano para tratamento de artrite